The additional role of anti-nucleosome antibodies in the prediction of renal damage in systemic lupus erythematosus based on CSTAR (XXV)

Objectives The predominant determinant of an unfavorable prognosis among Systemic Lupus Erythematosus (SLE) patients resides in the irreversible organ damage. This prospective cohort study aimed to identify the additional value of anti-nucleosome antibodies on organ damage accumulation in SLE patien...

Full description

Saved in:
Bibliographic Details
Published inLupus Vol. 33; no. 9; pp. 986 - 997
Main Authors Ding, Yufang, Zhou, Yangzhong, Zhao, Jiuliang, Wu, Chanyuan, Zhang, Shangzhu, Jiang, Nan, Qian, Junyan, Zhang, Li, Li, Jing, Xu, Dong, Leng, Xiaomei, Wang, Qian, Tian, Xinping, Li, Mengtao, Zeng, Xiaofeng
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.08.2024
Sage Publications Ltd
Subjects
Adult
Anti-DNA antibodies
Antibodies
Antibodies, Antinuclear - blood
Antibodies, Antinuclear - immunology
Autoantibodies
Autoantibodies - blood
Autoantibodies - immunology
China
Female
Follow-Up Studies
Humans
Kidney - immunology
Kidney - pathology
Kidneys
Lupus
Lupus Erythematosus, Systemic - complications
Lupus Erythematosus, Systemic - immunology
Lupus nephritis
Lupus Nephritis - immunology
Male
Middle Aged
Multivariate Analysis
Nucleosomes - immunology
Patients
Prognosis
Proportional Hazards Models
Prospective Studies
Registries
Systemic lupus erythematosus
Young Adult
China
lupus nephritis
anti-dsDNA antibodies
Systemic lupus erythematosus
anti-nucleosome antibodies
autoantibodies
Online AccessGet full text

Cover

Abstract Objectives The predominant determinant of an unfavorable prognosis among Systemic Lupus Erythematosus (SLE) patients resides in the irreversible organ damage. This prospective cohort study aimed to identify the additional value of anti-nucleosome antibodies on organ damage accumulation in SLE patients. Methods Based on the Chinese SLE Treatment and Research group (CSTAR) registry, demographic characteristics, autoantibodies profiles, and clinical manifestations were collected at baseline. Follow-up data were collected by reviewing clinical records. Results Of 2481 SLE patients with full follow-up data, 663 (26.7%) were anti-nucleosome antibodies positive and 1668 (68.0%) were anti-dsDNA antibodies positive. 764 (30.8%) patients developed new organ damage during a mean follow-up of 4.31 ± 2.60 years. At baseline, patients with positive anti-nucleosome antibodies have a higher rate of lupus nephritis (50.7% vs 36.2%, p < .001). According to the multivariable Cox regression analysis, both anti-nucleosome (HR = 1.30, 95% CI, 1.09-1.54, p < .001) and anti-dsDNA antibodies (HR=1.68, 95% CI, 1.38-2.05, p < .001) were associated with organ damage accumulation. Anti-nucleosome (HR = 2.51, 95% CI, 1.81-3.46, p < .001) and anti-dsDNA antibodies (HR = 1.69, 95% CI, 1.39-2.06, p < .001) were independent predictors for renal damage. Furthermore, the combination of the two antibodies can provide more accurate information about renal damage in overall SLE patients (HR = 3.19, 95% CI, 2.49-4.10, p < .001) and patients with lupus nephritis at baseline (HR = 2.86, 95% CI, 2.29-3.57, p < .001). Conclusion Besides anti-dsDNA antibodies, anti-nucleosome antibodies can also provide information about organ damage accrual during follow-up. The ability of co-positivity of anti-nucleosome and anti-dsDNA antibodies in predicting renal damage may lead to additional benefits in the follow-up of these patients.
AbstractList Objectives The predominant determinant of an unfavorable prognosis among Systemic Lupus Erythematosus (SLE) patients resides in the irreversible organ damage. This prospective cohort study aimed to identify the additional value of anti-nucleosome antibodies on organ damage accumulation in SLE patients. Methods Based on the Chinese SLE Treatment and Research group (CSTAR) registry, demographic characteristics, autoantibodies profiles, and clinical manifestations were collected at baseline. Follow-up data were collected by reviewing clinical records. Results Of 2481 SLE patients with full follow-up data, 663 (26.7%) were anti-nucleosome antibodies positive and 1668 (68.0%) were anti-dsDNA antibodies positive. 764 (30.8%) patients developed new organ damage during a mean follow-up of 4.31 ± 2.60 years. At baseline, patients with positive anti-nucleosome antibodies have a higher rate of lupus nephritis (50.7% vs 36.2%, p < .001). According to the multivariable Cox regression analysis, both anti-nucleosome (HR = 1.30, 95% CI, 1.09-1.54, p < .001) and anti-dsDNA antibodies (HR=1.68, 95% CI, 1.38-2.05, p < .001) were associated with organ damage accumulation. Anti-nucleosome (HR = 2.51, 95% CI, 1.81-3.46, p < .001) and anti-dsDNA antibodies (HR = 1.69, 95% CI, 1.39-2.06, p < .001) were independent predictors for renal damage. Furthermore, the combination of the two antibodies can provide more accurate information about renal damage in overall SLE patients (HR = 3.19, 95% CI, 2.49-4.10, p < .001) and patients with lupus nephritis at baseline (HR = 2.86, 95% CI, 2.29-3.57, p < .001). Conclusion Besides anti-dsDNA antibodies, anti-nucleosome antibodies can also provide information about organ damage accrual during follow-up. The ability of co-positivity of anti-nucleosome and anti-dsDNA antibodies in predicting renal damage may lead to additional benefits in the follow-up of these patients.
The predominant determinant of an unfavorable prognosis among Systemic Lupus Erythematosus (SLE) patients resides in the irreversible organ damage. This prospective cohort study aimed to identify the additional value of anti-nucleosome antibodies on organ damage accumulation in SLE patients.OBJECTIVESThe predominant determinant of an unfavorable prognosis among Systemic Lupus Erythematosus (SLE) patients resides in the irreversible organ damage. This prospective cohort study aimed to identify the additional value of anti-nucleosome antibodies on organ damage accumulation in SLE patients.Based on the Chinese SLE Treatment and Research group (CSTAR) registry, demographic characteristics, autoantibodies profiles, and clinical manifestations were collected at baseline. Follow-up data were collected by reviewing clinical records.METHODSBased on the Chinese SLE Treatment and Research group (CSTAR) registry, demographic characteristics, autoantibodies profiles, and clinical manifestations were collected at baseline. Follow-up data were collected by reviewing clinical records.Of 2481 SLE patients with full follow-up data, 663 (26.7%) were anti-nucleosome antibodies positive and 1668 (68.0%) were anti-dsDNA antibodies positive. 764 (30.8%) patients developed new organ damage during a mean follow-up of 4.31 ± 2.60 years. At baseline, patients with positive anti-nucleosome antibodies have a higher rate of lupus nephritis (50.7% vs 36.2%, p < .001). According to the multivariable Cox regression analysis, both anti-nucleosome (HR = 1.30, 95% CI, 1.09-1.54, p < .001) and anti-dsDNA antibodies (HR=1.68, 95% CI, 1.38-2.05, p < .001) were associated with organ damage accumulation. Anti-nucleosome (HR = 2.51, 95% CI, 1.81-3.46, p < .001) and anti-dsDNA antibodies (HR = 1.69, 95% CI, 1.39-2.06, p < .001) were independent predictors for renal damage. Furthermore, the combination of the two antibodies can provide more accurate information about renal damage in overall SLE patients (HR = 3.19, 95% CI, 2.49-4.10, p < .001) and patients with lupus nephritis at baseline (HR = 2.86, 95% CI, 2.29-3.57, p < .001).RESULTSOf 2481 SLE patients with full follow-up data, 663 (26.7%) were anti-nucleosome antibodies positive and 1668 (68.0%) were anti-dsDNA antibodies positive. 764 (30.8%) patients developed new organ damage during a mean follow-up of 4.31 ± 2.60 years. At baseline, patients with positive anti-nucleosome antibodies have a higher rate of lupus nephritis (50.7% vs 36.2%, p < .001). According to the multivariable Cox regression analysis, both anti-nucleosome (HR = 1.30, 95% CI, 1.09-1.54, p < .001) and anti-dsDNA antibodies (HR=1.68, 95% CI, 1.38-2.05, p < .001) were associated with organ damage accumulation. Anti-nucleosome (HR = 2.51, 95% CI, 1.81-3.46, p < .001) and anti-dsDNA antibodies (HR = 1.69, 95% CI, 1.39-2.06, p < .001) were independent predictors for renal damage. Furthermore, the combination of the two antibodies can provide more accurate information about renal damage in overall SLE patients (HR = 3.19, 95% CI, 2.49-4.10, p < .001) and patients with lupus nephritis at baseline (HR = 2.86, 95% CI, 2.29-3.57, p < .001).Besides anti-dsDNA antibodies, anti-nucleosome antibodies can also provide information about organ damage accrual during follow-up. The ability of co-positivity of anti-nucleosome and anti-dsDNA antibodies in predicting renal damage may lead to additional benefits in the follow-up of these patients.CONCLUSIONBesides anti-dsDNA antibodies, anti-nucleosome antibodies can also provide information about organ damage accrual during follow-up. The ability of co-positivity of anti-nucleosome and anti-dsDNA antibodies in predicting renal damage may lead to additional benefits in the follow-up of these patients.
The predominant determinant of an unfavorable prognosis among Systemic Lupus Erythematosus (SLE) patients resides in the irreversible organ damage. This prospective cohort study aimed to identify the additional value of anti-nucleosome antibodies on organ damage accumulation in SLE patients. Based on the Chinese SLE Treatment and Research group (CSTAR) registry, demographic characteristics, autoantibodies profiles, and clinical manifestations were collected at baseline. Follow-up data were collected by reviewing clinical records. Of 2481 SLE patients with full follow-up data, 663 (26.7%) were anti-nucleosome antibodies positive and 1668 (68.0%) were anti-dsDNA antibodies positive. 764 (30.8%) patients developed new organ damage during a mean follow-up of 4.31 ± 2.60 years. At baseline, patients with positive anti-nucleosome antibodies have a higher rate of lupus nephritis (50.7% vs 36.2%, < .001). According to the multivariable Cox regression analysis, both anti-nucleosome (HR = 1.30, 95% CI, 1.09-1.54, < .001) and anti-dsDNA antibodies (HR=1.68, 95% CI, 1.38-2.05, < .001) were associated with organ damage accumulation. Anti-nucleosome (HR = 2.51, 95% CI, 1.81-3.46, < .001) and anti-dsDNA antibodies (HR = 1.69, 95% CI, 1.39-2.06, < .001) were independent predictors for renal damage. Furthermore, the combination of the two antibodies can provide more accurate information about renal damage in overall SLE patients (HR = 3.19, 95% CI, 2.49-4.10, < .001) and patients with lupus nephritis at baseline (HR = 2.86, 95% CI, 2.29-3.57, < .001). Besides anti-dsDNA antibodies, anti-nucleosome antibodies can also provide information about organ damage accrual during follow-up. The ability of co-positivity of anti-nucleosome and anti-dsDNA antibodies in predicting renal damage may lead to additional benefits in the follow-up of these patients.
Objectives The predominant determinant of an unfavorable prognosis among Systemic Lupus Erythematosus (SLE) patients resides in the irreversible organ damage. This prospective cohort study aimed to identify the additional value of anti-nucleosome antibodies on organ damage accumulation in SLE patients. Methods Based on the Chinese SLE Treatment and Research group (CSTAR) registry, demographic characteristics, autoantibodies profiles, and clinical manifestations were collected at baseline. Follow-up data were collected by reviewing clinical records. Results Of 2481 SLE patients with full follow-up data, 663 (26.7%) were anti-nucleosome antibodies positive and 1668 (68.0%) were anti-dsDNA antibodies positive. 764 (30.8%) patients developed new organ damage during a mean follow-up of 4.31 ± 2.60 years. At baseline, patients with positive anti-nucleosome antibodies have a higher rate of lupus nephritis (50.7% vs 36.2%, p < .001). According to the multivariable Cox regression analysis, both anti-nucleosome (HR = 1.30, 95% CI, 1.09-1.54, p < .001) and anti-dsDNA antibodies (HR=1.68, 95% CI, 1.38-2.05, p < .001) were associated with organ damage accumulation. Anti-nucleosome (HR = 2.51, 95% CI, 1.81-3.46, p < .001) and anti-dsDNA antibodies (HR = 1.69, 95% CI, 1.39-2.06, p < .001) were independent predictors for renal damage. Furthermore, the combination of the two antibodies can provide more accurate information about renal damage in overall SLE patients (HR = 3.19, 95% CI, 2.49-4.10, p < .001) and patients with lupus nephritis at baseline (HR = 2.86, 95% CI, 2.29-3.57, p < .001). Conclusion Besides anti-dsDNA antibodies, anti-nucleosome antibodies can also provide information about organ damage accrual during follow-up. The ability of co-positivity of anti-nucleosome and anti-dsDNA antibodies in predicting renal damage may lead to additional benefits in the follow-up of these patients.
Author Li, Mengtao
Jiang, Nan
Zhang, Li
Li, Jing
Xu, Dong
Ding, Yufang
Tian, Xinping
Zhang, Shangzhu
Zeng, Xiaofeng
Wu, Chanyuan
Qian, Junyan
Wang, Qian
Zhou, Yangzhong
Zhao, Jiuliang
Leng, Xiaomei
Author_xml – sequence: 1
  givenname: Yufang
  orcidid: 0000-0001-6426-840X
  surname: Ding
  fullname: Ding, Yufang
  organization: Department of Rheumatology
– sequence: 2
  givenname: Yangzhong
  surname: Zhou
  fullname: Zhou, Yangzhong
  organization: Department of Rheumatology
– sequence: 3
  givenname: Jiuliang
  orcidid: 0000-0001-9308-2858
  surname: Zhao
  fullname: Zhao, Jiuliang
  organization: Department of Rheumatology
– sequence: 4
  givenname: Chanyuan
  surname: Wu
  fullname: Wu, Chanyuan
  organization: Department of Rheumatology
– sequence: 5
  givenname: Shangzhu
  surname: Zhang
  fullname: Zhang, Shangzhu
  organization: Department of Rheumatology
– sequence: 6
  givenname: Nan
  surname: Jiang
  fullname: Jiang, Nan
  organization: Department of Rheumatology
– sequence: 7
  givenname: Junyan
  surname: Qian
  fullname: Qian, Junyan
  organization: Department of Rheumatology
– sequence: 8
  givenname: Li
  orcidid: 0000-0003-0251-5457
  surname: Zhang
  fullname: Zhang, Li
  organization: Department of Rheumatology
– sequence: 9
  givenname: Jing
  surname: Li
  fullname: Li, Jing
  email: mengtao.li@cstar.org.cn
  organization: Department of Rheumatology
– sequence: 10
  givenname: Dong
  orcidid: 0000-0002-6413-3043
  surname: Xu
  fullname: Xu, Dong
  organization: Department of Rheumatology
– sequence: 11
  givenname: Xiaomei
  surname: Leng
  fullname: Leng, Xiaomei
  organization: Department of Rheumatology
– sequence: 12
  givenname: Qian
  surname: Wang
  fullname: Wang, Qian
  organization: Department of Rheumatology
– sequence: 13
  givenname: Xinping
  surname: Tian
  fullname: Tian, Xinping
  organization: Department of Rheumatology
– sequence: 14
  givenname: Mengtao
  orcidid: 0000-0003-4252-2889
  surname: Li
  fullname: Li, Mengtao
  email: mengtao.li@cstar.org.cn
  organization: Department of Rheumatology
– sequence: 15
  givenname: Xiaofeng
  surname: Zeng
  fullname: Zeng, Xiaofeng
  organization: Department of Rheumatology
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38853349$$D View this record in MEDLINE/PubMed
BookMark eNp1kcFu1DAQQC1URLeFD-CCLHEph7QeOxs7x2oFFKkSUrug3qKJPQFXSbzYyWH_gM_G6bYggTiNRvPejGbmhB2NYSTGXoM4B9D6QtQVSKGULEFWQip4xlZQal3kgjxiq6VeLMAxO0npXgihoK5esGNlzFqpsl6xn9vvxNE5P_kwYs9j6ImHjuM4-WKcbU8hhYEe8jY4T4n7kU9Z2kVy3i7awkdabIcDfqOFSPs00eAt7-fdnDjFfXYGnELKWYuJHM_i5nZ7ecPP7u6-vnvJnnfYJ3r1GE_Zlw_vt5ur4vrzx0-by-vCKimmAtadEaUiZ4ywGrCVaEHJlsh2uEZbCkRhbItlLVthazAE0lkh7Vq5ToA6ZWeHvrsYfsyUpmbwyVLf40hhTo0SVaWUrkqT0bd_ofdhjnnPhTJaaW2gztSbR2puB3LNLvoB4755unEG4ADYGFKK1P1GQDTLH5t__pid84OT8j3_jP2_8Av9AJyF
Cites_doi 10.3390/ijms20225799
10.1016/j.autrev.2014.10.003
10.2215/cjn.01910213
10.1016/j.jaut.2018.11.001
10.1681/asn.2019121285
10.1002/art.1780400928
10.1093/rheumatology/keh024
10.1002/jcla.20280
10.1016/j.jaut.2003.12.005
10.1038/sj.ki.5002133
10.3389/fimmu.2021.808008
10.1016/j.semnephrol.2011.06.009
10.1136/annrheumdis-2013-205171
10.1074/jbc.M112.341339
10.3899/jrheum.090019
10.1002/art.1780400506
10.1186/s13075-022-02766-1
10.1016/j.autrev.2008.06.005
10.1155/2014/809389
10.1177/0961203313499086
10.1038/ki.2011.484
10.1038/nrneph.2015.33
10.1007/s10875-012-9825-6
10.1016/j.jaut.2016.02.003
10.1093/rheumatology/kew377
10.3390/ijms16047917
10.1177/0961203315625460
10.1093/rheumatology/kez292
10.1056/NEJMra1100359
10.1177/0961203311417033
10.1681/asn.2009080805
10.1093/rheumatology/ker368
10.1007/s10067-017-3538-4
10.1177/0961203309345753
10.1002/art.1780350606
10.1186/s13075-017-1442-6
10.3389/fimmu.2019.01104
10.1002/art.40930
10.1002/acr.21664
10.1038/s41598-020-69608-5
10.1002/art.34473
10.1016/j.autrev.2012.07.002
10.1002/art.1780390303
10.1093/rheumatology/kep062
ContentType Journal Article
Copyright The Author(s) 2024
Copyright_xml – notice: The Author(s) 2024
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
H94
K9.
7X8
DOI 10.1177/09612033241260231
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList AIDS and Cancer Research Abstracts
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1477-0962
EndPage 997
ExternalDocumentID 38853349
10_1177_09612033241260231
10.1177_09612033241260231
Genre Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: National High Level Hospital Clinical Research Funding
  grantid: 2022-PUMCH-A-008
– fundername: Beijing Science and Technology Planning Project
  grantid: No. Z 201100005520022,23, 25-27
  funderid: https://doi.org/10.13039/501100012401
– fundername: Chinese National Key Technology R&D Program, Ministry of Science and Technology
  grantid: 2021YFC2501300
– fundername: CAMS Innovation Fund for Medical Sciences (CIFMS)
  grantid: 2021-I2M-1-005
GroupedDBID ---
-TM
.2E
.2F
.2G
.2J
.2N
.GJ
01A
0R~
18M
1~K
29L
31R
31S
31U
31X
31Y
31Z
36B
39C
4.4
53G
54M
5GY
5VS
7X7
88E
8FI
8FJ
8R4
8R5
AABMB
AABOD
AACKU
AACMV
AACTG
AADUE
AAEWN
AAGGD
AAGLT
AAGMC
AAJIQ
AAJOX
AAJPV
AAKGS
AANSI
AAPEO
AAQDB
AAQXH
AAQXI
AARDL
AARIX
AATAA
AATBZ
AAUAS
AAXOT
AAYTG
AAZBJ
ABAFQ
ABAWP
ABCCA
ABCJG
ABDBF
ABDWY
ABEIX
ABFWQ
ABHKI
ABHQH
ABIDT
ABJIS
ABJZC
ABKRH
ABLUO
ABOCM
ABPGX
ABPNF
ABQKF
ABQXT
ABRHV
ABUJY
ABUWG
ABVFX
ABVVC
ABYTW
ACARO
ACDSZ
ACDXX
ACFEJ
ACFMA
ACFYK
ACGBL
ACGFO
ACGFS
ACGZU
ACJER
ACJTF
ACLFY
ACLHI
ACLZU
ACOFE
ACOXC
ACPRK
ACROE
ACRPL
ACSIQ
ACUAV
ACUHS
ACUIR
ACXKE
ACXMB
ADBBV
ADDLC
ADEBD
ADEIA
ADMPF
ADNBR
ADNMO
ADNON
ADRRZ
ADSTG
ADTBJ
ADUCT
ADUKL
ADVBO
ADYCS
ADZZY
AECGH
AECVZ
AEDTQ
AEGXH
AEKYL
AENEX
AEPTA
AEQLS
AERKM
AESZF
AEUHG
AEWDL
AEWHI
AEXFG
AEXNY
AFEET
AFKBI
AFKRA
AFKRG
AFMOU
AFOSN
AFQAA
AFUIA
AFWMB
AGHKR
AGKLV
AGNHF
AGPXR
AGQPQ
AGWFA
AGWNL
AHDMH
AHMBA
AIAGR
AIGRN
AJABX
AJEFB
AJMMQ
AJSCY
AJUZI
AJXAJ
ALIPV
ALKWR
ALMA_UNASSIGNED_HOLDINGS
AMCVQ
ANDLU
ARTOV
ASPBG
AUTPY
AUVAJ
AVWKF
AYAKG
AZFZN
AZQEC
B3H
B8M
B8O
B8R
B8Z
B93
B94
BBRGL
BDDNI
BENPR
BKIIM
BKNYI
BKSCU
BPACV
BPHCQ
BSEHC
BVXVI
BWJAD
BYIEH
C45
CBRKF
CCPQU
CDWPY
CFDXU
CORYS
CQQTX
CS3
CUTAK
DB0
DC-
DC0
DD-
DD0
DE-
DF0
DO-
DOPDO
DU5
DV7
DV9
D~Y
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
EPL
ESX
F5P
FEDTE
FHBDP
FYUFA
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
H13
HF~
HMCUK
HVGLF
HZ~
J8X
K.F
K.J
K9-
M0R
M1P
N9A
O9-
OVD
P.B
P2P
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
Q1R
Q2X
Q7K
Q7L
Q7R
Q7U
Q7X
Q82
Q83
ROL
S01
SASJQ
SAUOL
SCNPE
SDB
SFB
SFC
SFK
SFN
SFT
SGA
SGO
SGP
SGR
SGV
SGX
SGZ
SHG
SNB
SPJ
SPQ
SPV
SQCSI
STM
SV3
TEORI
TUS
UKHRP
ZONMY
ZPPRI
ZRKOI
ZSSAH
AAYXX
AJGYC
CITATION
AAEJI
AAPII
AJVBE
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
7T5
H94
K9.
7X8
ID FETCH-LOGICAL-c320t-15f8043ed880c71ab2ac132beecfa5ac40aa08cba492b0c918e12dc02c53df013
ISSN 0961-2033
1477-0962
IngestDate Tue Aug 05 09:27:28 EDT 2025
Sat Jul 26 02:50:52 EDT 2025
Mon Jul 21 06:04:22 EDT 2025
Tue Jul 01 05:31:06 EDT 2025
Tue Jun 17 22:27:19 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords lupus nephritis
anti-dsDNA antibodies
Systemic lupus erythematosus
anti-nucleosome antibodies
autoantibodies
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c320t-15f8043ed880c71ab2ac132beecfa5ac40aa08cba492b0c918e12dc02c53df013
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-6413-3043
0000-0003-0251-5457
0000-0001-9308-2858
0000-0003-4252-2889
0000-0001-6426-840X
PMID 38853349
PQID 3087377819
PQPubID 32637
PageCount 12
ParticipantIDs proquest_miscellaneous_3066337648
proquest_journals_3087377819
pubmed_primary_38853349
crossref_primary_10_1177_09612033241260231
sage_journals_10_1177_09612033241260231
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20240800
2024-08-00
2024-Aug
20240801
PublicationDateYYYYMMDD 2024-08-01
PublicationDate_xml – month: 8
  year: 2024
  text: 20240800
PublicationDecade 2020
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: England
– name: London
PublicationTitle Lupus
PublicationTitleAlternate Lupus
PublicationYear 2024
Publisher SAGE Publications
Sage Publications Ltd
Publisher_xml – name: SAGE Publications
– name: Sage Publications Ltd
References Aringer, Costenbader, Daikh 2019; 71
Mohan, Putterman 2015; 11
Gensous, Marti, Barnetche 2017; 19
Sui, Lin, Xu 2013; 33
Jacob, Viard 1992; 1
Reátegui-Sokolova, Ugarte-Gil, Gamboa-Cárdenas 2017; 36
Yung, Cheung, Zhang 2010; 21
Alduraibi, Fatima, Hamilton 2022; 24
Kalaaji, Fenton, Mortensen 2007; 71
Tsokos 2011; 365
Hochberg 1997; 40
Moura, Lima, Barbosa 2009; 23
Yaniv, Twig, Shor 2015; 14
Bombardier, Gladman, Urowitz 1992; 35
Petri, Singh, Tesfasyone 2009; 36
Rekvig 2019; 10
Gómez-Puerta, Burlingame, Cervera 2008; 7
Yap, Lai 2015; 16
Tsang, Bultink, Heslinga 2017; 56
Olson, Lee, Prince 2013; 8
Fava, Petri 2019; 96
Bruce, O'Keeffe, Farewell 2015; 74
Maddison, Farewell, Isenberg 2002; 29
Bizzaro, Villalta, Giavarina 2012; 12
Ghirardello, Doria, Zampieri 2004; 22
Heidenreich, Mayer, Herold 2009; 18
Segura, Bernstein, McDonnell 2020; 59
Gladman, Goldsmith, Urowitz 2000; 27
Gatto, Iaccarino, Ghirardello 2016; 69
Rodriguez-Jimenez, Perez-Guerrero, Gamez-Nava 2020; 10
Lopez, Davidson, Beeby 2012; 51
Hahn, McMahon, Wilkinson 2012; 64
Krishnan, Wang, Marion 2012; 82
Hung, Chen, Lan 2011; 20
Petri, Orbai, Alarcón 2012; 64
Gladman, Urowitz, Goldsmith 1997; 40
Mejia-Vilet, Zhang, Cruz 2020; 31
Ghiggeri, D'Alessandro, Bartolomeo 2019; 20
Simón, Cabiedes, Ortiz 2004; 43
Li, Zhang, Leng 2013; 22
Martin, Leffler, Blom 2012; 287
Li, Leng, Li 2014; 2014
Chambers, Allen, Rahman 2009; 48
van der Vlag, Berden 2011; 31
Zhao, Bai, Zhu 2016; 25
Rekvig 2021; 12
Gladman, Ginzler, Goldsmith 1996; 39
bibr35-09612033241260231
bibr45-09612033241260231
bibr32-09612033241260231
bibr25-09612033241260231
bibr12-09612033241260231
bibr15-09612033241260231
bibr22-09612033241260231
bibr2-09612033241260231
bibr4-09612033241260231
bibr7-09612033241260231
bibr17-09612033241260231
bibr27-09612033241260231
bibr43-09612033241260231
bibr30-09612033241260231
bibr33-09612033241260231
bibr46-09612033241260231
bibr13-09612033241260231
bibr9-09612033241260231
bibr36-09612033241260231
bibr23-09612033241260231
bibr26-09612033241260231
bibr40-09612033241260231
bibr20-09612033241260231
bibr10-09612033241260231
bibr19-09612033241260231
bibr3-09612033241260231
bibr6-09612033241260231
bibr16-09612033241260231
Gladman DD (bibr21-09612033241260231) 2000; 27
bibr29-09612033241260231
bibr39-09612033241260231
bibr31-09612033241260231
bibr47-09612033241260231
bibr11-09612033241260231
bibr37-09612033241260231
bibr34-09612033241260231
bibr44-09612033241260231
bibr8-09612033241260231
bibr14-09612033241260231
bibr1-09612033241260231
Maddison P (bibr41-09612033241260231) 2002; 29
bibr5-09612033241260231
bibr42-09612033241260231
bibr18-09612033241260231
bibr28-09612033241260231
bibr38-09612033241260231
Jacob L (bibr24-09612033241260231) 1992; 1
References_xml – volume: 40
  start-page: 809
  year: 1997
  end-page: 813
  article-title: The reliability of the systemic lupus international collaborating clinics/American College of Rheumatology damage index in patients with systemic lupus erythematosus
  publication-title: Arthritis Rheum
– volume: 12
  start-page: 97
  year: 2012
  end-page: 106
  article-title: Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis
  publication-title: Autoimmun Rev
– volume: 2014
  start-page: 809389
  year: 2014
  article-title: Chinese SLE treatment and research group registry: III. association of autoantibodies with clinical manifestations in Chinese patients with systemic lupus erythematosus
  publication-title: J Immunol Res
– volume: 21
  start-page: 1912
  year: 2010
  end-page: 1927
  article-title: Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis
  publication-title: J Am Soc Nephrol
– volume: 36
  start-page: 845
  year: 2017
  end-page: 852
  article-title: Serum uric acid levels contribute to new renal damage in systemic lupus erythematosus patients
  publication-title: Clin Rheumatol
– volume: 20
  start-page: 1404
  year: 2011
  end-page: 1410
  article-title: Antinucleosome antibodies as a potential biomarker for the evaluation of renal pathological activity in patients with proliferative lupus nephritis
  publication-title: Lupus
– volume: 31
  start-page: 376
  year: 2011
  end-page: 389
  article-title: Lupus nephritis: role of antinucleosome autoantibodies
  publication-title: Semin Nephrol
– volume: 39
  start-page: 363
  year: 1996
  end-page: 369
  article-title: The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus
  publication-title: Arthritis Rheum
– volume: 71
  start-page: 664
  year: 2007
  end-page: 672
  article-title: Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis
  publication-title: Kidney Int
– volume: 82
  start-page: 184
  year: 2012
  end-page: 192
  article-title: Anti-DNA autoantibodies initiate experimental lupus nephritis by binding directly to the glomerular basement membrane in mice
  publication-title: Kidney Int
– volume: 31
  start-page: 1335
  year: 2020
  end-page: 1347
  article-title: Urinary soluble CD163: a novel noninvasive biomarker of activity for lupus nephritis
  publication-title: J Am Soc Nephrol
– volume: 69
  start-page: 1
  year: 2016
  end-page: 11
  article-title: Clinical and pathologic considerations of the qualitative and quantitative aspects of lupus nephritogenic autoantibodies: a comprehensive review
  publication-title: J Autoimmun
– volume: 40
  start-page: 1725
  year: 1997
  article-title: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
  publication-title: Arthritis Rheum
– volume: 8
  start-page: 1702
  year: 2013
  end-page: 1708
  article-title: Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis
  publication-title: Clin J Am Soc Nephrol
– volume: 22
  start-page: 235
  year: 2004
  end-page: 240
  article-title: Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients
  publication-title: J Autoimmun
– volume: 18
  start-page: 1276
  year: 2009
  end-page: 1280
  article-title: Sensitivity and specificity of autoantibody tests in the differential diagnosis of lupus nephritis
  publication-title: Lupus
– volume: 22
  start-page: 1192
  year: 2013
  end-page: 1199
  article-title: Chinese SLE Treatment and Research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus
  publication-title: Lupus
– volume: 33
  start-page: 378
  year: 2013
  end-page: 387
  article-title: Simultaneous positivity for anti-DNA, anti-nucleosome and anti-histone antibodies is a marker for more severe lupus nephritis
  publication-title: J Clin Immunol
– volume: 64
  start-page: 2677
  year: 2012
  end-page: 2686
  article-title: Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
  publication-title: Arthritis Rheum
– volume: 25
  start-page: 652
  year: 2016
  end-page: 657
  article-title: Chinese SLE Treatment and Research group (CSTAR) registry VII: prevalence and clinical significance of serositis in Chinese patients with systemic lupus erythematosus
  publication-title: Lupus
– volume: 27
  start-page: 373
  year: 2000
  end-page: 376
  article-title: The systemic lupus international collaborating clinics/American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison
  publication-title: J Rheumatol
– volume: 7
  start-page: 606
  year: 2008
  end-page: 611
  article-title: Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value
  publication-title: Autoimmun Rev
– volume: 1
  start-page: 425
  year: 1992
  end-page: 431
  article-title: Anti-DNA antibodies and their relationships with anti-histone and anti-nucleosome specificities
  publication-title: Eur J Med
– volume: 16
  start-page: 7917
  year: 2015
  end-page: 7931
  article-title: Pathogenesis of renal disease in systemic lupus erythematosus--the role of autoantibodies and lymphocytes subset abnormalities
  publication-title: Int J Mol Sci
– volume: 24
  start-page: 87
  year: 2022
  article-title: Lupus nephritis correlates with B cell interferon-β, anti-Smith, and anti-DNA: a retrospective study
  publication-title: Arthritis Res Ther
– volume: 20
  start-page: 2019
  year: 2019
  article-title: An update on antibodies to necleosome components as biomarkers of sistemic lupus erythematosus and of lupus flares
  publication-title: Int J Mol Sci
– volume: 36
  start-page: 2476
  year: 2009
  end-page: 2480
  article-title: Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study
  publication-title: J Rheumatol
– volume: 10
  start-page: 12698
  year: 2020
  article-title: Anti-nucleosome antibodies increase the risk of renal relapse in a prospective cohort of patients with clinically inactive systemic lupus erythematosus
  publication-title: Sci Rep
– volume: 64
  start-page: 797
  year: 2012
  end-page: 808
  article-title: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis
  publication-title: Arthritis Care Res
– volume: 48
  start-page: 673
  year: 2009
  end-page: 675
  article-title: Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years
  publication-title: Rheumatology
– volume: 96
  start-page: 1
  year: 2019
  end-page: 13
  article-title: Systemic lupus erythematosus: diagnosis and clinical management
  publication-title: J Autoimmun
– volume: 23
  start-page: 19
  year: 2009
  end-page: 23
  article-title: Anti-C1q antibodies: association with nephritis and disease activity in systemic lupus erythematosus
  publication-title: J Clin Lab Anal
– volume: 74
  start-page: 1706
  year: 2015
  end-page: 1713
  article-title: Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
  publication-title: Ann Rheum Dis
– volume: 29
  start-page: 913
  year: 2002
  end-page: 917
  article-title: The rate and pattern of organ damage in late onset systemic lupus erythematosus
  publication-title: J Rheumatol
– volume: 365
  start-page: 2110
  year: 2011
  end-page: 2121
  article-title: Systemic lupus erythematosus
  publication-title: N Engl J Med
– volume: 71
  start-page: 1400
  year: 2019
  end-page: 1412
  article-title: 2019 European league against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
  publication-title: Arthritis Rheumatol
– volume: 59
  start-page: 524
  year: 2020
  end-page: 533
  article-title: Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort
  publication-title: Rheumatology
– volume: 287
  start-page: 33733
  year: 2012
  end-page: 33744
  article-title: Annexin A2 and A5 serve as new ligands for C1q on apoptotic cells
  publication-title: J Biol Chem
– volume: 14
  start-page: 75
  year: 2015
  end-page: 79
  article-title: A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients
  publication-title: Autoimmun Rev
– volume: 51
  start-page: 491
  year: 2012
  end-page: 498
  article-title: Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort
  publication-title: Rheumatology
– volume: 35
  start-page: 630
  year: 1992
  end-page: 640
  article-title: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE
  publication-title: Arthritis Rheum
– volume: 56
  start-page: 121
  year: 2017
  end-page: 128
  article-title: Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus
  publication-title: Rheumatology
– volume: 10
  start-page: 1104
  year: 2019
  article-title: The dsDNA, anti-dsDNA antibody, and lupus nephritis: what we agree on, what must Be done, and what the best strategy forward could Be
  publication-title: Front Immunol
– volume: 11
  start-page: 329
  year: 2015
  end-page: 341
  article-title: Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis
  publication-title: Nat Rev Nephrol
– volume: 19
  start-page: 238
  year: 2017
  article-title: Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review
  publication-title: Arthritis Res Ther
– volume: 12
  start-page: 808008
  year: 2021
  article-title: The anti-DNA antibodies: their specificities for unique DNA structures and their unresolved clinical impact-A system criticism and a hypothesis
  publication-title: Front Immunol
– volume: 43
  start-page: 220
  year: 2004
  end-page: 224
  article-title: Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker
  publication-title: Rheumatology
– ident: bibr4-09612033241260231
  doi: 10.3390/ijms20225799
– ident: bibr2-09612033241260231
  doi: 10.1016/j.autrev.2014.10.003
– ident: bibr28-09612033241260231
  doi: 10.2215/cjn.01910213
– ident: bibr6-09612033241260231
  doi: 10.1016/j.jaut.2018.11.001
– ident: bibr47-09612033241260231
  doi: 10.1681/asn.2019121285
– ident: bibr14-09612033241260231
  doi: 10.1002/art.1780400928
– ident: bibr34-09612033241260231
  doi: 10.1093/rheumatology/keh024
– ident: bibr9-09612033241260231
  doi: 10.1002/jcla.20280
– ident: bibr33-09612033241260231
  doi: 10.1016/j.jaut.2003.12.005
– ident: bibr35-09612033241260231
  doi: 10.1038/sj.ki.5002133
– ident: bibr44-09612033241260231
  doi: 10.3389/fimmu.2021.808008
– ident: bibr10-09612033241260231
  doi: 10.1016/j.semnephrol.2011.06.009
– ident: bibr11-09612033241260231
  doi: 10.1136/annrheumdis-2013-205171
– ident: bibr37-09612033241260231
  doi: 10.1074/jbc.M112.341339
– ident: bibr26-09612033241260231
  doi: 10.3899/jrheum.090019
– ident: bibr22-09612033241260231
  doi: 10.1002/art.1780400506
– ident: bibr46-09612033241260231
  doi: 10.1186/s13075-022-02766-1
– ident: bibr29-09612033241260231
  doi: 10.1016/j.autrev.2008.06.005
– ident: bibr17-09612033241260231
  doi: 10.1155/2014/809389
– ident: bibr13-09612033241260231
  doi: 10.1177/0961203313499086
– ident: bibr38-09612033241260231
  doi: 10.1038/ki.2011.484
– ident: bibr5-09612033241260231
  doi: 10.1038/nrneph.2015.33
– volume: 1
  start-page: 425
  year: 1992
  ident: bibr24-09612033241260231
  publication-title: Eur J Med
– ident: bibr8-09612033241260231
  doi: 10.1007/s10875-012-9825-6
– ident: bibr39-09612033241260231
  doi: 10.1016/j.jaut.2016.02.003
– volume: 29
  start-page: 913
  year: 2002
  ident: bibr41-09612033241260231
  publication-title: J Rheumatol
– ident: bibr43-09612033241260231
  doi: 10.1093/rheumatology/kew377
– volume: 27
  start-page: 373
  year: 2000
  ident: bibr21-09612033241260231
  publication-title: J Rheumatol
– ident: bibr36-09612033241260231
  doi: 10.3390/ijms16047917
– ident: bibr16-09612033241260231
  doi: 10.1177/0961203315625460
– ident: bibr12-09612033241260231
  doi: 10.1093/rheumatology/kez292
– ident: bibr1-09612033241260231
  doi: 10.1056/NEJMra1100359
– ident: bibr7-09612033241260231
  doi: 10.1177/0961203311417033
– ident: bibr27-09612033241260231
  doi: 10.1681/asn.2009080805
– ident: bibr40-09612033241260231
  doi: 10.1093/rheumatology/ker368
– ident: bibr42-09612033241260231
  doi: 10.1007/s10067-017-3538-4
– ident: bibr31-09612033241260231
  doi: 10.1177/0961203309345753
– ident: bibr19-09612033241260231
  doi: 10.1002/art.1780350606
– ident: bibr25-09612033241260231
  doi: 10.1186/s13075-017-1442-6
– ident: bibr45-09612033241260231
  doi: 10.3389/fimmu.2019.01104
– ident: bibr3-09612033241260231
  doi: 10.1002/art.40930
– ident: bibr18-09612033241260231
  doi: 10.1002/acr.21664
– ident: bibr32-09612033241260231
  doi: 10.1038/s41598-020-69608-5
– ident: bibr15-09612033241260231
  doi: 10.1002/art.34473
– ident: bibr30-09612033241260231
  doi: 10.1016/j.autrev.2012.07.002
– ident: bibr20-09612033241260231
  doi: 10.1002/art.1780390303
– ident: bibr23-09612033241260231
  doi: 10.1093/rheumatology/kep062
SSID ssj0003196
Score 2.4169073
Snippet Objectives The predominant determinant of an unfavorable prognosis among Systemic Lupus Erythematosus (SLE) patients resides in the irreversible organ damage....
The predominant determinant of an unfavorable prognosis among Systemic Lupus Erythematosus (SLE) patients resides in the irreversible organ damage. This...
Objectives The predominant determinant of an unfavorable prognosis among Systemic Lupus Erythematosus (SLE) patients resides in the irreversible organ damage....
SourceID proquest
pubmed
crossref
sage
SourceType Aggregation Database
Index Database
Publisher
StartPage 986
SubjectTerms Adult
Anti-DNA antibodies
Antibodies
Antibodies, Antinuclear - blood
Antibodies, Antinuclear - immunology
Autoantibodies
Autoantibodies - blood
Autoantibodies - immunology
China
Female
Follow-Up Studies
Humans
Kidney - immunology
Kidney - pathology
Kidneys
Lupus
Lupus Erythematosus, Systemic - complications
Lupus Erythematosus, Systemic - immunology
Lupus nephritis
Lupus Nephritis - immunology
Male
Middle Aged
Multivariate Analysis
Nucleosomes - immunology
Patients
Prognosis
Proportional Hazards Models
Prospective Studies
Registries
Systemic lupus erythematosus
Young Adult
Title The additional role of anti-nucleosome antibodies in the prediction of renal damage in systemic lupus erythematosus based on CSTAR (XXV)
URI https://journals.sagepub.com/doi/full/10.1177/09612033241260231
https://www.ncbi.nlm.nih.gov/pubmed/38853349
https://www.proquest.com/docview/3087377819
https://www.proquest.com/docview/3066337648
Volume 33
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZKJyFe0LiXDWQkJC5TpsRxbo_dYJqQ4IUOylPlOI5WiSVV2zxsv4C_wr_kHF-SpmMS4yVqfE1zvvgcH38-JuQ1V3mcceF7ZZwzjyd-5AkluCfwOOuoDPF0HGRbfIlPz_inaTQdDH5vsJaadX4or_66r-R_pAppIFfcJXsLybaNQgL8BvnCFSQM13-WMRKCrD_PMQXhZc29CgMV16v6Qun7vEa6oGM1Lpa4PuOMxaXC2oW4QP4OlDDRnefy4GezaFYHanlpQrvWK7hDtVfgEsPx18kY2X7pdPrN-RPcxmqs15rI9tSUH00prJrUjuq60amQdnVeb2YIsxg0b9AD06Z_byw7oLpsLKKts4LxlirXeh3jAERoYl8cKjPm8iTxIKM3KNsSBnzZxgibucjZ5s6Qe6_rAb0Sjb1hZ2ClwLSNWXXTi7m9pQtbhmLgwqBvN3GH7DCYkbAh2RkffTg6adU-jmU6sKP9h3YJXUf32m6kbwRdm9n0WIXa0Jnskvt2hkLHBm4PyEBVD8ndz5aD8Yj8AtTRDnUUUUfrkm6hjnaoo_OKAoJohzosr1FHDeqwhEMd1aijPdRRjToKFTXq6FvA3LvH5Ozk4-T41LPneXgyZP7aC6Iy9XmoCtAZMglEzoQMQpYrJUsRCcl9IfxU5oJnLPdlFqQqYIX0mYzCooS5yhMyrOpKPSO0hFkB42UI6klyqJ_5qUrAVg15HBWChyPy3r3g2cKEbZndKNIR2XcimNmvezXDSJlhAm1mI_KqzYaxFxfURKXqBsuAvQ4amqcj8tSIru0tTFPc5Q6136Asu4ZvfIznt3nmPXKv-772yXC9bNQLMI_X-UsLzD8SUrHZ
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+additional+role+of+anti-nucleosome+antibodies+in+the+prediction+of+renal+damage+in+systemic+lupus+erythematosus+based+on+CSTAR+%28XXV%29&rft.jtitle=Lupus&rft.au=Ding%2C+Yufang&rft.au=Zhou%2C+Yangzhong&rft.au=Zhao%2C+Jiuliang&rft.au=Wu%2C+Chanyuan&rft.date=2024-08-01&rft.issn=0961-2033&rft.eissn=1477-0962&rft.volume=33&rft.issue=9&rft.spage=986&rft.epage=997&rft_id=info:doi/10.1177%2F09612033241260231&rft.externalDBID=n%2Fa&rft.externalDocID=10_1177_09612033241260231
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0961-2033&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0961-2033&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0961-2033&client=summon